Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 12.77
NVIV's Cash to Debt is ranked lower than
57% of the 839 Companies
in the Global Biotechnology industry.

( Industry Median: 67.24 vs. NVIV: 12.77 )
Ranked among companies with meaningful Cash to Debt only.
NVIV' s 10-Year Cash to Debt Range
Min: 0.11  Med: 57.89 Max: No Debt
Current: 12.77
F-Score: 2
Z-Score: 7.84
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
ROE (%) -275.30
NVIV's ROE (%) is ranked lower than
94% of the 765 Companies
in the Global Biotechnology industry.

( Industry Median: -30.76 vs. NVIV: -275.30 )
Ranked among companies with meaningful ROE (%) only.
NVIV' s 10-Year ROE (%) Range
Min: -775.86  Med: -546.32 Max: -195.09
Current: -275.3
-775.86
-195.09
ROA (%) -144.40
NVIV's ROA (%) is ranked lower than
90% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: -26.31 vs. NVIV: -144.40 )
Ranked among companies with meaningful ROA (%) only.
NVIV' s 10-Year ROA (%) Range
Min: -1218.1  Med: -266.67 Max: 42.86
Current: -144.4
-1218.1
42.86
ROC (Joel Greenblatt) (%) -1609.70
NVIV's ROC (Joel Greenblatt) (%) is ranked lower than
67% of the 815 Companies
in the Global Biotechnology industry.

( Industry Median: -356.32 vs. NVIV: -1609.70 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NVIV' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -13352.31  Med: -1292.80 Max: 334.39
Current: -1609.7
-13352.31
334.39
EBITDA Growth (3Y)(%) -33.30
NVIV's EBITDA Growth (3Y)(%) is ranked lower than
82% of the 430 Companies
in the Global Biotechnology industry.

( Industry Median: -3.50 vs. NVIV: -33.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NVIV' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -62.2  Med: -33.30 Max: 543.1
Current: -33.3
-62.2
543.1
EPS Growth (3Y)(%) -32.30
NVIV's EPS Growth (3Y)(%) is ranked lower than
81% of the 411 Companies
in the Global Biotechnology industry.

( Industry Median: -5.60 vs. NVIV: -32.30 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NVIV' s 10-Year EPS Growth (3Y)(%) Range
Min: -62.2  Med: -32.30 Max: 544.7
Current: -32.3
-62.2
544.7
» NVIV's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with NVIV

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 39.16
NVIV's P/B is ranked lower than
98% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: 5.01 vs. NVIV: 39.16 )
Ranked among companies with meaningful P/B only.
NVIV' s 10-Year P/B Range
Min: 0  Med: 0.00 Max: 67.4
Current: 39.16
0
67.4
Current Ratio 1.68
NVIV's Current Ratio is ranked lower than
79% of the 809 Companies
in the Global Biotechnology industry.

( Industry Median: 4.40 vs. NVIV: 1.68 )
Ranked among companies with meaningful Current Ratio only.
NVIV' s 10-Year Current Ratio Range
Min: 0.14  Med: 1.27 Max: 14.81
Current: 1.68
0.14
14.81
Quick Ratio 1.68
NVIV's Quick Ratio is ranked lower than
74% of the 809 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. NVIV: 1.68 )
Ranked among companies with meaningful Quick Ratio only.
NVIV' s 10-Year Quick Ratio Range
Min: 0.14  Med: 1.27 Max: 14.81
Current: 1.68
0.14
14.81

Valuation & Return

vs
industry
vs
history
Price/Net Cash 52.20
NVIV's Price/Net Cash is ranked lower than
91% of the 481 Companies
in the Global Biotechnology industry.

( Industry Median: 8.97 vs. NVIV: 52.20 )
Ranked among companies with meaningful Price/Net Cash only.
NVIV' s 10-Year Price/Net Cash Range
Min: 4.72  Med: 18.37 Max: 48
Current: 52.2
4.72
48
Price/Net Current Asset Value 46.06
NVIV's Price/Net Current Asset Value is ranked lower than
93% of the 572 Companies
in the Global Biotechnology industry.

( Industry Median: 8.11 vs. NVIV: 46.06 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
NVIV' s 10-Year Price/Net Current Asset Value Range
Min: 4.44  Med: 17.33 Max: 34.94
Current: 46.06
4.44
34.94
Price/Tangible Book 39.15
NVIV's Price/Tangible Book is ranked lower than
96% of the 702 Companies
in the Global Biotechnology industry.

( Industry Median: 5.88 vs. NVIV: 39.15 )
Ranked among companies with meaningful Price/Tangible Book only.
NVIV' s 10-Year Price/Tangible Book Range
Min: 3.83  Med: 14.49 Max: 29.7
Current: 39.15
3.83
29.7
Earnings Yield (Greenblatt) (%) -7.31
NVIV's Earnings Yield (Greenblatt) (%) is ranked lower than
53% of the 912 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. NVIV: -7.31 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
NVIV' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -29.4  Med: 0.00 Max: 1000
Current: -7.31
-29.4
1000

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
InVivo Therapeutics Holdings Corp. was incorporated on April 2, 2003, under the name of Design Source, Inc. The Company develops novel biomaterial technologies for the treatment of spinal cord injuries and hydrogels for therapeutics delivery. It is also developing an injectable, resorbable family of hydrogels for localized, controlled release of small molecules and proteins. Under the CMCC License, the Company has the right to sublicense the patents and have full control and authority over the development and commercialization of the licensed products, including clinical trials, manufacturing, marketing, and regulatory filings. The Comany also own the rights to the data generated pursuant to the CMCC License. The Company competes with major drug companies, specialized biotechnology firms, academic institutions, government agencies and private and public research institutions. The Company is subject to evolving federal, state and local environmental, health and safety laws and regulations.
» More Articles for NVIV

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
InVivo Therapeutics to Present at Cantor Fitzgerald’s Inaugural Healthcare Conference Jul 01 2015
InVivo Therapeutics to Present at Cantor Fitzgerald’s Inaugural Healthcare Conference Jul 01 2015
InVivo Therapeutics Announces Rutgers New Jersey Medical School as New Clinical Site for... Jun 30 2015
InVivo Therapeutics Announces Rutgers New Jersey Medical School as New Clinical Site for... Jun 30 2015
InVivo Therapeutics is Added to Russell Global, Russell 3000®, Russell 2000®, and Russell... Jun 29 2015
InVivo Therapeutics is Added to Russell Global, Russell 3000®, Russell 2000®, and Russell... Jun 29 2015
InVivo Therapeutics to Present at the 33rd Annual Symposium of the National Neurotrauma Society Jun 23 2015
InVivo Therapeutics to Present at the 33rd Annual Symposium of the National Neurotrauma Society Jun 23 2015
InVivo Therapeutics Receives Notice of Allowance on Patent Covering Broader Compositions for... Jun 22 2015
InVivo Therapeutics Receives Notice of Allowance on Patent Covering Broader Compositions for... Jun 22 2015
InVivo Therapeutics Announces Posting of Management Presentation Recording from Annual Shareholders... Jun 19 2015
InVivo Therapeutics Announces Posting of Management Presentation Recording from Annual Shareholders... Jun 19 2015
InVivo Therapeutics Co-Founder Dr. Robert Langer to Highlight InVivo Scientific Progress in Closing... Jun 18 2015
InVivo Therapeutics Co-Founder Dr. Robert Langer to Highlight InVivo Scientific Progress in Closing... Jun 18 2015
INVIVO THERAPEUTICS HOLDINGS CORP. Files SEC form 8-K, Change in Directors or Principal Officers,... Jun 16 2015
InVivo Therapeutics Announces Appointment of Ann Merrifield as Lead Director Jun 16 2015
InVivo Therapeutics Announces Appointment of Ann Merrifield as Lead Director Jun 16 2015
InVivo Therapeutics Announces James Guest, M.D., Ph.D., Has Joined Scientific Advisory Board Jun 15 2015
InVivo Therapeutics Announces James Guest, M.D., Ph.D., Has Joined Scientific Advisory Board Jun 15 2015
NVIV: InVivo Enrolls Patient No. 3, Statistics Point To Evidence Of Clinical Benefit So Far Jun 05 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK